We are live on ! Find out more
OREX

Orexigen Therapeutics
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

147 hedge funds and large institutions have $654M invested in Orexigen Therapeutics in 2014 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 31 increasing their positions, 52 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

50% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 18

18% more call options, than puts

Call options by funds: $10.2M | Put options by funds: $8.6M

15% more funds holding

Funds holding: 128 → 147 (+19)

4.63% more ownership

Funds ownership: 82.32% → 86.95% (+4.6%)

6% less capital inflows, than outflows

Capital inflows: $69.5M | Capital outflows: $74M

40% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 52

Holders
147
Holders Change
+19
Holders Change %
+14.84%
% of All Funds
3.9%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.11%
New
27
Increased
31
Reduced
52
Closed
18
Calls
$10.2​M
Puts
$8.6​M
Net Calls
+$1.57​M
Net Calls Change
+$3.57​M

OREX Hedge Fund Activity: Q4 2014 in Review

147 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics (OREX) for Q4 2014, worth a combined $654M — up 52% from $432M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new OREX positions and 18 closed out — a net gain of 9 holders — while 31 added to existing stakes and 52 trimmed.

The largest buyer was Samlyn Capital, adding an estimated $17M. The largest seller was Capital Research Global Investors, cutting an estimated $9.9M.

  • 147 institutional investors held Orexigen Therapeutics (OREX) as of Q4 2014, up from 128 in Q3 2014.
  • Funds reported $654M of Orexigen Therapeutics stock for Q4 2014, up 52% quarter-over-quarter.
  • 27 funds opened new Orexigen Therapeutics positions in Q4 2014 and 18 closed out, a net change of +9 holders.
  • The largest Orexigen Therapeutics buyer in Q4 2014 was Samlyn Capital, an estimated $17M added.
  • The largest Orexigen Therapeutics seller in Q4 2014 was Capital Research Global Investors, an estimated $9.9M sold.

Based on aggregated 13F filings for Q4 2014.